Savara Inc.

SVRA

US8051111016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
4.09 ^USD	-0.49%		+0.25%	-12.98%

05-21	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating	MT
05-09	Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Savara Inc. Appoints Dhaval Desai as Head of Clinical Development and Brian Maurer as Head of Clinical Operations

May 13, 2021 at 04:05 pm

Savara Inc. announced that Dhaval Desai, M.D. Appointed Head of Clinical Development and Brian Maurer Appointed Head of Clinical Operations.

Latest news about Savara Inc.

Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating	05-21	MT
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection	04-12	CI
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024	04-08	CI
Transcript : Savara Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:00 AM	03-14
Savara Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
Piper Sandler Adjusts Price Target on Savara to $16 From $7, Maintains Overweight Rating	03-04	MT
JMP Securities Starts Savara With Market Outperform Rating, $8 Price Target	02-15	MT
Savara Insider Sold Shares Worth $395,900, According to a Recent SEC Filing	12-29	MT
Savara Insider Sold Shares Worth $442,291, According to a Recent SEC Filing	12-29	MT
Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis	12-21	CI
Savara Inc.(NasdaqGS:SVRA) added to NASDAQ Biotechnology Index	12-18	CI
Savara Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Guggenheim Starts Savara With Buy Rating, $7 Price Target	11-07	MT
Savara Inc.(NasdaqGS:SVRA) added to S&P Global BMI Index	23-09-18	CI
HC Wainwright Adjusts Price Target on Savara to $6 From $3, Keeps Buy Rating	23-08-14	MT
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Savara Prices $80 Million Brokered Offering of Common Shares, Warrants	23-07-13	MT
Savara Completes Enrolment in Study of Molgramostim to Treat Autoimmune Pulmonary Alveolar Proteinosis	23-06-26	MT
Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis	23-06-26	CI
Savara Inc.(NasdaqGS:SVRA) added to Russell Small Cap Comp Value Index	23-06-23	CI
Savara Inc.(NasdaqGS:SVRA) added to Russell 3000 Index	23-06-23	CI
Savara Inc.(NasdaqGS:SVRA) added to Russell 3000E Growth Index	23-06-23	CI
Savara Inc.(NasdaqGS:SVRA) added to Russell 3000E Index	23-06-23	CI

Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Companyâs lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Jefferies Global Healthcare Conference - Fireside Chat

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.09 USD

Average target price

9 USD

Spread / Average Target

+120.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAVARA INC.	-12.98%	565M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs

Savara Inc.

Equities

SVRA

US8051111016

Biotechnology & Medical Research

Savara Inc. Appoints Dhaval Desai as Head of Clinical Development and Brian Maurer as Head of Clinical Operations

Latest news about Savara Inc.

Chart Savara Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs